Navigation Links
CET Life Sciences Center Welcomes Belmont University School of Pharmacy as New Tenant
Date:7/1/2008

oviding laboratory and equipment infrastructure to support their promising research."

Belmont's School of Pharmacy announced last week that it has received approval from The Accreditation Council for Pharmacy Education (ACPE) to seat its first class of 75 students for the 2008-09 academic year.

Belmont University, host of the 2008 Town Hall Presidential Debate, is a fast-growing community of nearly 4,800 students who come from almost every state and more than 25 countries. Committed to being a leader among teaching universities, Belmont brings together the best of liberal arts and professional education in a Christian community of learning and service. Belmont's purpose is to help students explore their passions and develop their talents to meet the world's needs. With more than 75 areas of study, 12 master's programs and three doctoral degrees, there is no limit to the ways Belmont University can expand an individual's horizon. For more information, visit http://www.belmont.edu.

Cumberland Emerging Technologies, Inc. (http://www.cet-fund.com) is a joint initiative between Cumberland Pharmaceuticals Inc., Vanderbilt University and the Tennessee Technology Development Corporation. The mission of CET is to bring biomedical technologies and products conceived at Vanderbilt and other regional research centers to the marketplace. CET helps manage the development and commercialization process for select projects, and provides expertise on intellectual property, regulatory, manufacturing and marketing issues that are critical to successful new biomedical products. CET's Life Sciences Center, located in Nashville, Tennessee, provides laboratory space, equipment and infrastructure to early-stage life sciences companies.


'/>"/>
SOURCE Cumberland Emerging Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
5. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
6. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
7. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
8. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
9. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
10. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
11. The Pittsburgh Life Sciences Greenhouse Adds New Companies to its Investment Portfolio
Post Your Comments:
*Name:
*Comment:
*Email: